ScreenerHero
VVYVivoryon Therapeutics N.V.
AMS · NL · Healthcare · Biotechnology · vivoryon.com
1.145EUR+1.78%Mkt Cap: 36.86M $P/E: —

Vivoryon Therapeutics N.V. operates as a clinical stage biopharmaceutical company that focuses on research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-…

Industry Peers

Biotechnology
Screen all
VX1
Vertex Pharmaceuticals Incorporated
$130.23BUSDP/E 32.1
VRTX
Vertex Pharmaceuticals Incorporated
$139.84BUSDP/E 32.2
REGN
Regeneron Pharmaceuticals, Inc.
$85.11BUSDP/E 20.4
MRNA
Moderna, Inc.
$69.62BUSD
ARGX
argenx SE
$61.34BUSDP/E 39.8
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$46.01BUSD
ONC
BeOne Medicines AG
$41.76BUSDP/E 66.2
RPRX
Royalty Pharma Plc Class A
$35.67BUSDP/E 33.2
ALNY
Alnylam Pharmaceuticals, Inc.
$32.46BUSDP/E 42.3
INSM
Insmed Incorporated
$28.53BUSD
22UA
BioNTech SE
$26.14BUSD
INCY
Incyte Corporation
$25.79BUSDP/E 16.2
GMAB
Genmab A/S
$20.83BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$17.03BUSDP/E 20.0
BBIO
BridgeBio Pharma, Inc.
$16.41BUSD
EXEL
Exelixis, Inc.
$13.48BUSDP/E 17.1
BMRN
BioMarin Pharmaceutical Inc.
$13.42BUSDP/E 187.4
CORT
Corcept Therapeutics Incorporated
$12.87BUSDP/E 264.5

Key Statistics

Company
Market Cap36.86M $
Enterprise Value33.64M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-9.62M $
Revenue/Share—
Last Price1.145 EUR
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees13
CountryNL
SectorHealthcare
IndustryBiotechnology
ISINNL00150002Q7
Valuation
P/E (Trailing)—
P/E (Forward)-3.63
PEG—
EV/EBITDA-4.62
EV/Revenue—
P/S—
P/B9.30
EPS (TTM)-0.33
EPS (Forward)-0.31
52W Range
1.02015% of range1.840
52W High1.840 EUR
52W Low1.020 EUR
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-187.29%
ROA-117.76%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-9.19M $
CapEx (TTM)6.52K $
FCF Margin—
FCF Yield-11.08%
Net Debt-2.58M $
Net Debt/EBITDA0.35
Balance Sheet
Debt/Equity0.02
Current Ratio4.56
Quick Ratio4.03
Book Value/Sh0.1210 EUR
Cash/Share0.0830 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)6.850 EUR
Upside (mean)+498.3%
Target Range6.850 EUR – 6.850 EUR
# Analysts1
Ownership
Shares Out.29.61M
Float26.35M
Insiders17.99%
Institutions8.91%
Technical
SMA 501.158 (-1.1%)
SMA 2001.348 (-15.0%)
Beta1.45
S&P 52W Chg18.16%
Avg Vol (30d)44.86K
Avg Vol (10d)55.06K
Technical Indicators
RSI (14)44.7
MACD-0.0154
MACD Signal-0.0090
MACD Hist.-0.0064
BB Upper1.236 EUR
BB Middle1.164 EUR
BB Lower1.092 EUR
BB Width12.34%
ATR (14)0.0543 EUR
Vol Ratio (20d)1.00x